Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717415 · ClinicalTrials.gov registry record · Phase 1
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03717415 is a Phase 1 study that was terminated before completion, run by Deciphera Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT03717415, a Phase 1 study, was terminated before completion, sponsored by Deciphera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic solid tumors.
Interventions
- DRUG Carboplatin
- DRUG Rebastinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717415
The ClinicalTrials.gov registry entry for NCT03717415 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT03717415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717415 about?
NCT03717415 is a clinical study titled "A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors". This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic solid tumors.
What is the current status of trial NCT03717415?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2019-01-02. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT03717415?
The interventions under investigation include: Carboplatin (DRUG), Rebastinib (DRUG).
Who is sponsoring clinical trial NCT03717415?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.